Truist Financial Has Lowered Expectations for Integra LifeSciences (NASDAQ:IART) Stock Price

Integra LifeSciences (NASDAQ:IART) had its target price cut by equities research analysts at Truist Financial from $19.00 to $15.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a “hold” rating on the life sciences company’s stock. Truist Financial’s price target would suggest a potential upside of 15.19% from the stock’s previous close.

Other equities analysts have also issued research reports about the stock. BMO Capital Markets reduced their target price on shares of Integra LifeSciences from $18.00 to $15.00 and set a “market perform” rating on the stock in a report on Monday, October 5th. Wall Street Zen downgraded Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Weiss Ratings lowered Integra LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. Citigroup reissued a “neutral” rating and issued a $15.00 price objective (down from $19.00) on shares of Integra LifeSciences in a research report on Monday, October 5th. Finally, UBS Group initiated coverage on Integra LifeSciences in a research note on Tuesday, July 28th. They set a “neutral” rating and a $19.00 price objective on the stock. One equities research analyst has rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average target price of $16.71.

Integra LifeSciences Trading Down 6.0%

Shares of NASDAQ IART traded down $0.83 during midday trading on Wednesday, hitting $13.02. The stock had a trading volume of 344,372 shares, compared to its average volume of 900,237. The company has a quick ratio of 2.11, a current ratio of 3.60 and a debt-to-equity ratio of 1.75. Integra LifeSciences has a 1-year low of $8.70 and a 1-year high of $20.49. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of -144.81, a PEG ratio of 0.72 and a beta of 1.21. The company has a fifty day moving average price of $16.07 and a 200 day moving average price of $15.40.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. The company had revenue of $418.76 million during the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, analysts predict that Integra LifeSciences will post 2.47 earnings per share for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IART. Paradigm Capital Management Inc. NY boosted its position in Integra LifeSciences by 50.6% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock valued at $37,800,000 after buying an additional 1,347,700 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Integra LifeSciences by 12.4% during the second quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company’s stock valued at $26,241,000 after acquiring an additional 160,814 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Integra LifeSciences by 71.4% during the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock valued at $13,325,000 after acquiring an additional 589,408 shares in the last quarter. Invenomic Capital Management LP increased its position in shares of Integra LifeSciences by 78.3% during the fourth quarter. Invenomic Capital Management LP now owns 1,055,941 shares of the life sciences company’s stock worth $13,115,000 after acquiring an additional 463,729 shares during the last quarter. Finally, Glenmede Trust Co. NA increased its position in shares of Integra LifeSciences by 27.4% during the first quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock worth $9,276,000 after acquiring an additional 211,774 shares during the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.